Immune checkpoint blockade (ICB) is an immunotherapy class that releases inhibitory checkpoints on antitumor immunity, most often by blocking checkpoint pathways to restore T-cell activity and improve tumor killing. It is used across multiple cancers, including lung cancer, dmmr colorectal cancer, immune excluded tumors, and metastatic ovarian cancer, and is also discussed in the context of nk cells-based cancer immunotherapy advances. Recent literature highlights that ICB can be more effective when combined with kras inhibitors, low-dose radiotherapy, or time-gated redox sensitization strategies, and that response prediction is being refined in metastatic dMMR colorectal cancer. The Key Facts indicate it is a prior regimen class in patients who had progressed on earlier immune checkpoint inhibitor-based regimens, underscoring its role in the setting of immune-refractory disease. Overall, the evidence points to both broad clinical utility and persistent limitations from immune evasion and resistance, especially in tumors with poor baseline responsiveness such as ovarian cancer.
Lung cancer
- A phase II study in advanced immuno-refractory metastatic non-small cell lung cancer evaluated immune checkpoint blockade in combination with alirocumab, reflecting ongoing efforts to overcome prior ICB resistance (PMID:41940540).
- A 2026 review in Apoptosis noted that immunotherapy has improved outcomes in lung cancer, but many patients still have unmet needs because of immune evasion and resistance (PMID:41998294).
- The study context indicates patients had progressed on prior immune checkpoint inhibitor-based regimens, making ICB a prior treatment class in this setting (PMID:41940540).
Colorectal cancer and response prediction
- In metastatic dMMR colorectal cancer, immune checkpoint blockade was reported to induce frequent and durable responses, supporting its established activity in this molecular subtype (PMID:41995725).
- An integrated immune-enhanced multi-omics platform was used to identify predictors of ICB response, highlighting movement toward biomarker-guided treatment selection (PMID:41995725).
- This work emphasizes response prediction rather than only treatment delivery, suggesting a precision-oncology direction for ICB use (PMID:41995725).
Tumor microenvironment and combination strategies
- In immune-excluded solid tumors, combining immune checkpoint blockade with low-dose radiotherapy was associated with enhanced CD8+ T cell functionality, supporting a microenvironment-reprogramming strategy (PMID:41995577).
- A programmable DNAzyme nanocatalyst was reported to create a defined redox sensitization window in which ICB produced stronger immunomodulation, indicating time-dependent optimization of therapy (PMID:41981590).
- In pancreatic cancer, KRAS inhibitors were described as producing more potent antitumor effects when combined with ICB, linking checkpoint therapy to oncogenic pathway inhibition (PMID:41642174).
- A nano-enabled STING agonist delivery platform was presented as a potent antitumor immunotherapy approach, providing a combination context in which ICB-related immune activation is being advanced (PMID:41955504).
Ovarian cancer and resistance biology
- In metastatic ovarian cancer, immune checkpoint blockade was described as having very limited clinical efficacy in this context, underscoring a resistant disease setting (PMID:41984099).
- The ovarian cancer study focused on improving APC function of B cells through fatty-acid-metabolism reprogramming, pointing to immune-metabolic barriers that may limit ICB benefit (PMID:41984099).
- In clear cell renal cell carcinoma, lactate remodeling and immune evasion were linked to resistance biology, relevant to understanding why ICB can fail in some tumors (PMID:42028950).
NK-cell and broader immunotherapy advances
- A review of NK cell-mediated killing highlighted immune checkpoint blockade as part of recent advances in NK cell-based cancer immunotherapy (PMID:41799416).
- This positions ICB not only as a T-cell-directed therapy but also within broader innate-adaptive immune engineering efforts (PMID:41799416).